Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant

Completed · Phase 2

Conditions studied: Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific

In brief

RATIONALE: Thalidomide may interfere with the body's ability to recognize transplanted bone marrow cells as foreign and may help treat patients with graft-versus-host disease. PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating patients who have chronic graft-versus-host disease following bone marrow transplantation.

Key facts

Study ID

NCT00003894

Run by

Roswell Park Cancer Institute

People needed

36

Starts

1999-03-01

Expected to finish

2002-06-01

Last updated by the study team

2011-03-07

Who can join

Age: 3 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arkansas Children's Hospital — Little Rock, Arkansas, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Louisiana State University School of Medicine — New Orleans, Louisiana, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Simmons Cancer Center - Dallas — Dallas, Texas, United States
• Brooke Army Medical Center — Fort Sam Houston, Texas, United States
• Cook Children's Medical Center - Fort Worth — Fort Worth, Texas, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• Cancer Center of the Medical College of Wisconsin — Milwaukee, Wisconsin, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.